- Home
- HQL
as 10-07-2025 3:30pm EST
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 440.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 120.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.34 - $14.37 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Saba Capital Management, L.P. | HQL | 10% Owner | Sep 22 '25 | Sell | $14.14 | 41,623 | $588,549.22 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Sep 19 '25 | Sell | $14.10 | 6,989 | $98,544.90 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Sep 18 '25 | Sell | $14.07 | 40,208 | $565,726.56 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Sep 17 '25 | Sell | $13.99 | 24,328 | $340,348.72 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Sep 16 '25 | Sell | $13.99 | 2,026 | $28,343.74 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Sep 15 '25 | Sell | $14.13 | 700 | $9,891.00 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Sep 11 '25 | Sell | $14.28 | 15,116 | $215,856.48 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Sep 2 '25 | Sell | $14.04 | 14,083 | $197,725.32 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Aug 29 '25 | Sell | $13.89 | 23,723 | $329,512.47 | 2,837,633 | |
| Saba Capital Management, L.P. | HQL | N/A | Aug 26 '25 | Sell | $13.83 | 400 | $5,532.00 | 2,837,633 |
Latest abrdn Life Sciences Investors Shares of Beneficial Interest News
HQL Breaking Stock News: Dive into HQL Ticker-Specific Updates for Smart Investing
GOBankingRates
4 months ago
7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
GOBankingRates
4 months ago
3 International Vacations That Are Cheaper Than an iPhone
GOBankingRates
4 months ago
Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck
Yahoo Finance
4 months ago
This week in Trumponomics: Too bad TACO isn’t true
The Guardian
4 months ago
Starmer says Farage would spook the City and give us Truss 2 – he could be right
Yahoo Finance Video
4 months ago
AI ecosystem isn't just Nvidia: Unlock it further with this ETF
Benzinga
4 months ago
Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?
Reuters
4 months ago
Ford recalls more than 29,000 vehicles in the US, NHTSA says
Compare HQL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HQL abrdn Life Sciences Investors Shares of Beneficial Interest - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.